Shares of NASDAQ CLLS opened at $1.90 on Friday. The stock has a market cap of $105.61 million, a PE ratio of -1.47 and a beta of 3.09. Cellectis has a 52-week low of $0.96 and a 52-week high of $3.77. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.92 and a current ratio of 1.92. The business has a fifty day moving average of $2.17 and a two-hundred day moving average of $2.35.
Cellectis (NASDAQ:CLLS - Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.05. Cellectis had a negative return on equity of 78.90% and a negative net margin of 401.83%. The firm had revenue of $9.50 million during the quarter, compared to the consensus estimate of $6.00 million. As a group, equities research analysts expect that Cellectis will post -0.54 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. XTX Topco Ltd acquired a new stake in shares of Cellectis during the 2nd quarter worth approximately $29,000. First Affirmative Financial Network acquired a new stake in shares of Cellectis during the third quarter worth $45,000. Principal Financial Group Inc. raised its position in Cellectis by 2.9% in the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company's stock valued at $817,000 after buying an additional 12,467 shares during the last quarter. Baillie Gifford & Co. grew its stake in shares of Cellectis by 1.3% during the 1st quarter. Baillie Gifford & Co. now owns 827,248 shares of the biotechnology company's stock worth $2,192,000 after acquiring an additional 10,605 shares in the last quarter. Finally, Long Focus Capital Management LLC boosted its holdings in Cellectis by 2.9% during the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company's stock worth $8,634,000 after purchasing an additional 130,000 shares during the last quarter. Institutional investors and hedge funds own 63.90% of the company's stock.
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Cellectis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellectis wasn't on the list.
While Cellectis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.